CYP19A1 and Hepatic steatosis: In a small sample of participants with hepatic steatosis, ARO-ANG3 also decreased atherogenic lipoproteins, and, notably, no increase in liver fat was observed after repeat dosing, with most participants showing a numerical decline in liver fat content18.